Aytu Biopharma, INC Form 4 insider transactions
NASDAQ
4/A: Aytu BioPharma Director, Vivian H. Liu, Reports Amended Statement of Changes in Beneficial Ownership
Vivian H. Liu, a director of Aytu BioPharma, filed an amended Form 4 to correct the total shares beneficially owned following a transaction on August 11, 2023.
NASDAQ
Chief Commercial Officer Greg Pyszczymuka acquired 7,000 employee stock options in Aytu BioPharma, Inc. on November 6, 2024.
NASDAQ
Chief Commercial Officer Greg Pyszczymuka reports the vesting of restricted stock units into Aytu BioPharma common shares.
NASDAQ
Chief Commercial Officer Greg Pyszczymuka reports the vesting and conversion of restricted stock units into common shares of Aytu BioPharma.
NASDAQ
Nantahala Capital Management, along with Wilmot B. Harkey and Daniel Mack, reported changes in their beneficial ownership of Aytu BioPharma, Inc. securities, including warrants exercisable for common stock.
NASDAQ
Greg Pyszczymuka, Chief Commercial Officer of Aytu BioPharma, reports the vesting of restricted stock units and subsequent ownership of common shares.